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To date, more than 7000 rare diseases have been identified which affect 30–40 million patients in the
European Union (EU), and some 250 new rare diseases are described every year [1, 2]. Primary or
secondary lung involvement occurs in ∼5% of rare diseases; therefore, approximately 1–2 million people in
the EU are likely to be affected by rare pulmonary diseases [3]. This means that if individuals suffering
from rare diseases are by definition “uncommon”, rare conditions affect a very large number of people.
Arguably, in the past few years interest in rare diseases has grown, as demonstrated by the agendas of
politicians and health authorities, but too little attention is still paid to ultra-rare diseases. Although no
legal definition of an “ultra-rare” disease has yet been established, this subcategory was introduced by the
National Institute for Health and Care Excellence for drugs with indications for diseases that have a
prevalence of <1 per 50000 persons [4–6]. According to EU legislation, patients suffering from a rare
condition are entitled to the same standard of care as other patients [7]. In some European countries, such
as Italy and the Netherlands, the right to healthcare is protected constitutionally and everyone is entitled
to equal access to public healthcare [8]. Moreover, article two of the European Convention on Human
Rights (ECHR) states that “Everyone’s right to life shall be protected by law” [9].
Also for these reasons, European legislation was introduced in 2000 to drive the development of orphan
drugs, arriving much later than the USA Orphan Drug Act of 1983. This legislation requires that the
pharmaceutical industry has a right to: 1) obtain protocol assistance at a reduced rate; 2) access the
centralised authorisation procedure; 3) enjoy lower registration fees; and 4) benefit from 10 years of market
exclusivity after registration [7, 10–12]. This has led to the authorisation by the European Medicines
Agency of 124 new orphan drugs in the EU between 2000 and 2015, of which about one-third were for
ultra-rare diseases (www.ema.europa.eu/ema/). .
In the respiratory field, there are several ultra-rare diseases: lymphangiomatosis [13], pleuro-parenchymal
fibroelasytosis, pulmonary alveolar microlithiasis [14], ataxia telangiectasia [15], pulmonary alveolar proteinosis,
lysosomal storage diseases, pulmonary dendriform ossification, light chain deposition disorders [16],
Birt–Hogg–Dubè syndrome [16], rare vascular disorders and vasculitis along with several others.
The research and development process for new drugs to treat very rare diseases requires significant
investment and the allocation of highly sophisticated resources, a situation which raises ethical as well as
social issues. It is indeed fair to wonder whether society and the public at large should bear the high cost
of research activities benefitting a very small number of individuals, albeit affected by severe and chronic
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ailments, or whether this goes against the principle of equality. Strangely, patients with rare and, at times,
unknown conditions tend to absorb even higher resources than patients affected by more common
diseases generally described as “normal”.
As stated by HUGES et al. [5], the principle of equality would argue against special consideration being given
to patients with rare conditions in the allocation of healthcare resources. Investing substantial amounts of
resources in rare conditions may be viewed as unethical from a utilitarian point of view, as it does not
maximise the benefits for society as a whole [5]. But who should take care of this, if not the government?
A key factor underlying the failure of many orphan drugs to meet proposed standards for
cost-effectiveness is that manufacturers need to generate revenues to allow them to recoup research and
development expenditures for a small group of patients. This challenge inevitably leads to elevated
acquisition costs.
For EU member states to make decisions on reimbursement, it is crucial to acquire greater insights into the
balance between expenses and health gains for a specific drug, in order to determine the “value for money”
for orphan drugs. Conversely, the public does not seem prepared to deny patients treatment merely on the
basis of cost [17]. Accordingly, drug acquisition costs are inversely correlated with prevalence.
However, despite high costs and considering the rarity of these diseases, the outlay for these drugs
represents only a small proportion of the global drug budget of a modern European healthcare system.
Another important issue is how research should be carried out for ultra-rare diseases, along with the issue
of quality. Clinical evidence on ultra-rare drugs for chronic diseases is frequently based on observations
among small numbers of patients in short-term studies utilising surrogate outcomes rather than long-term
trials [18]. Typically, in such studies, the primary end-points are surrogate; the relationship between the
surrogate end-point and survival or mortality or other clinically relevant end-points is not always clear [18].
For example, improved walking distance induced by drugs affecting pulmonary arterial hypertension,
although statistically significant, is of questionable clinical relevance. The efficacy of anti-cancer drugs has
been measured in terms of tumour response or time-to-progression rather than survival or quality of life.
JOPPI et al. [18] report that in some cases the trial was too short with respect to the natural history of the
rare disease evaluated: 20 weeks for agalsidase-β or 18 months for agalsidase-α in the treatment of Fabry
disease; 12 weeks for pegvisomant acting on resistant acromegaly and also for drugs that are active in
pulmonary hypertension or epilepsy.
However, although less stringent criteria may be adopted for orphan drugs than for common drugs, this
should not be a good reason not to guarantee the best available treatment to patients with rare diseases
[18]. A critical step in generating data is to establish disease-specific registries including longitudinal data
on all affected patients. SCHULLER et al. [12] suggest that ideally registries would start before drugs are
marketed, so as to produce data about the natural history of the disease. Accordingly, EU countries need
to work in close cooperation.
Organising care for individuals with ultra-rare conditions demands a different and highly specific
approach. Recent research has shown that a well-organised, patient-centred, multidisciplinary approach is
more patient friendly and generates better outcomes than the current care model [19].
National governments must develop strategies to drive clinical research, and incentives to encourage
teaching hospitals to care for and investigate rare and ultra-rare diseases. Major efforts are also needed to
train specialists with enough expertise to promptly recognise ultra-rare diseases, explore differential
diagnoses and offer the most advanced treatment options. All this will be facilitated by supra-national
partnerships between the few specialists with an interest in specific conditions, ranging from the
establishment of rare diseases registries (to significantly increase patient populations) to web-based options
(extremely fast contacts and real-time data sharing thanks to teleconsultations that also permit contacts
among patients) [20]. Rare and ultra-rare conditions represent a major research challenge since they
highlight and amplify the need for cooperation and sharing of know-how on the one hand, and for
channelling efforts towards dedicated centres of excellence to develop and offer multidisciplinary skills on
the other. Is this a challenge that can be met?
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